Grufity logoGrufity logo

CFMS

2.14USD+0.08(+3.88%)Market Closed

ConforMIS Inc

Market Summary

USD2.14+0.08Market Closed
3.88%

CFMS Stock Price

RSI Chart

Valuation

Market Cap

22.6M

Price/Earnings

-0.37

Price/Sales

0.37

Price/Cashflow

-0.73

MarketCap/EBT

-0.37

Price/Sales

Profitability

Operating Margin

38.28%

EBT Margin

-99.95%

Return on Equity

-82.4%

Return on Assets

-51.59%

Fundamentals

Revenue

Revenue (TTM)

60.1M

Revenue Y/Y

-3.29%

Revenue Q/Q

-9.88%

Earnings

Earnings (TTM)

-62.7M

Earnings Y/Y

-17.18%

Earnings Q/Q

2.07%

Price Action

52 Week Range

1.2024.25
(Low)(High)

Last 7 days

5.4%

Last 30 days

-33.4%

Last 90 days

-67.8%

Trailing 12 Months

-91.2%

Financial Health

Current Ratio

5.71

Debt/Equity

0.28

Debt/Cashflow

-1.52

Investor Care

Shares Dilution (1Y)

0.98%

Diluted EPS (TTM)

-0.35

Peers (Alternatives to ConforMIS)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-10.97% 36.28%
185.5K
28.0K
144.70% 331.94%
115.4B
31.1B
-7.32% -29.47%
22.17
3.71
-1.67% 34.08%
86.7B
17.9B
1.82% -7.99%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
9.71% -21.89%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
2.22% 0.83%
38.21
3.25
-6.81% -14.96%
43.9B
5.4B
-11.99% -33.30%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
7.06% 6.92%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
10.81% -24.63%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-15.13% 7.13%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-29.09% -70.24%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
13.84% 14.29%
-26.38
14.01
34.44% -10.05%
1.0B
795.9M
23.41% -17.93%
-131.34
1.33
8.11% 182.50%
994.0M
154.8M
-3.42% -51.74%
-10.57
6.72
60.29% -2309.58%
606.7M
236.2M
-6.08% -40.13%
-16.43
2.57
-8.79% -175.19%

Financials for ConforMIS

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.8%6061102100101
Gross Profit-5.0%2223656668
Operating Expenses-0.7%7575746965
  S&GA Expenses-3.3%2627262524
  R&D Expenses0.8%1616161514
Earnings Before Taxes-3.7%-62.72-60.49-6.84-2.327
Net Income-3.7%-62.73-60.50-6.94-2.417
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-10.8%105117129145158
  Current Assets-11.9%89101111127138
    Cash Equivalents-18.0%60738310197
  Inventory7.7%1817161514
  Net PPE-3.8%99101011
Liabilities-1.0%4344434543
  Current Liabilities-0.7%1818161815
  Long Term Debt0.2%2020202021
    LT Debt, Non Current0.2%2020202021
Shareholder's Equity-16.7%617386101115
  Retained Earnings-2.7%-577.61-562.41-546.90-530.90-514.90
  Additional Paid-In Capital0.1%635634633633631
Shares Outstanding-0.2%188188185186186
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-5.6%-32,811.00-31,070.00-16,984.00-8,399.00-18,417.00
  Share Based Compensation-5.6%3,4173,6213,6063,8153,574
Cashflow From Investing11.3%-2,065.00-2,329.00-2,627.00-2,300.00-2,080.00
Cashflow From Financing-0.7%-2,087.00-2,073.00-2,092.0082,80384,890

Risks

What is the probability of a big loss on CFMS?

100%


Probability that ConforMIS stock will be more than 20% underwater in next one year

100%


Probability that ConforMIS stock will be more than 30% underwater in next one year.

95.4%


Probability that ConforMIS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CFMS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ConforMIS was unfortunately bought at previous high price.

Returns

Cumulative Returns on CFMS

-54.5%


7-Year Cumulative Returns

-51.7%


5-Year Cumulative Returns

-64.3%


3-Year Cumulative Returns

What are the long-term rolling returns for CFMS?

FIve years rolling returns for ConforMIS.

Which funds bought or sold CFMS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Invst, LLC
UNCHANGED
-
-12,000
18,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
JANE STREET GROUP, LLC
REDUCED
-90.14
-80,000
4,000
-%
2022-11-15
STATE STREET CORP
UNCHANGED
-
-100,000
118,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
UNCHANGED
-
-88
103
-%
2022-11-15
NOMURA HOLDINGS INC
REDUCED
-82.63
-85,000
9,000
-%
2022-11-14
RENAISSANCE TECHNOLOGIES LLC
ADDED
4.11
-708,000
911,000
-%
2022-11-14
BRIDGEWAY CAPITAL MANAGEMENT, LLC
UNCHANGED
-
-3,000
3,000
-%
2022-11-14
LAZARD ASSET MANAGEMENT LLC
SOLD OFF
-100
-9,000
-
-%
2022-11-14
VANGUARD GROUP INC
REDUCED
-8.69
-1,451,000
1,412,000
-%

1–10 of 48

Latest Funds Activity

Are funds buying CFMS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CFMS

ConforMIS News

InvestorsObserver

ConforMIS Inc (CFMS) Stock Gains 35.44% This Week: Is It a Good Pick?.2 days ago

Benzinga

CFMS Fair Value

Recent SEC filings of ConforMIS

View All Filings
Date Filed Form Type Document
Nov 09, 2022
8-K
Current Report
Nov 02, 2022
8-K
Current Report
Nov 02, 2022
10-Q
Quarterly Report
Oct 28, 2022
8-K
Current Report
Sep 16, 2022
DEFA14A
DEFA14A
Sep 16, 2022
DEF 14A
DEF 14A
Sep 02, 2022
PRE 14A
PRE 14A

Latest Insider Trading transactions for CFMS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-05-24
JOHNSTON PHILIP W
ACQUIRED
-
-
130,870
-
2022-05-24
Langdale Bradley
ACQUIRED
-
-
130,870
-
2022-05-24
HOWE ROBERT S
ACQUIRED
-
-
304,615
CFO & TREASURER
2022-05-24
Milligan Michael D.
ACQUIRED
-
-
130,870
-
2022-05-24
BIENKOWSKI CARRIE
ACQUIRED
-
-
130,870
-
2022-05-24
Fishetti Gary P
ACQUIRED
-
-
261,740
-
2022-05-24
FALLON KENNETH P III
ACQUIRED
-
-
130,870
-
2022-05-07
Augusti Mark A
SOLD
-10,279.8
0.459
-22,396
President & CEO
2022-03-14
Pedulla Denise E
ACQUIRED
-
-
450,000
CLO & SECRETARY
2022-02-17
HOWE ROBERT S
SOLD
-7,514.05
0.6513
-11,537
CFO & TREASURER

1–10 of 50

Mark A. Augusti
310
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

CFMS Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue    
Total revenue$ 13,784$ 14,253$ 44,630$ 84,436
Cost of revenue8,9278,23128,57224,703
Gross profit4,8576,02216,05859,733
Operating expenses    
Sales and marketing5,5626,43418,78917,851
Research and development3,6763,54812,11310,738
General and administrative7,6087,40724,63420,762
Total operating expenses16,84617,38955,53649,351
(Loss) income from operations(11,989)(11,367)(39,478)10,382
Other income and expenses    
Interest income12204377
Interest expense(526)(601)(1,430)(1,802)
Other income0007,252
Foreign currency exchange transaction loss(2,672)(996)(5,931)(2,302)
Total other (expenses) income(3,186)(1,577)(7,318)3,225
(Loss) income before income taxes(15,175)(12,944)(46,796)13,607
Income tax provision2729(39)44
Net (loss) income$ (15,202)$ (12,973)$ (46,757)$ 13,563
Net (loss) income per share - basic (in USD per share)$ (0.08)$ (0.07)$ (0.26)$ 0.08
Net (loss) income per share - diluted (in USD per share)$ (0.08)$ (0.07)$ (0.26)$ 0.08
Weighted average common shares outstanding - basic (in shares)181,216,213178,452,296180,238,044162,646,412
Weighted average common shares outstanding - diluted (in shares)181,216,213178,452,296180,238,044167,369,631
Product    
Revenue    
Total revenue$ 13,642$ 14,130$ 43,668$ 43,040
Royalty and licensing    
Revenue    
Total revenue$ 142$ 123$ 962$ 41,396

CFMS Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current Assets  
Cash and cash equivalents$ 59,581$ 100,556
Accounts receivable, net9,4729,079
Royalty and licensing receivable141280
Inventories, net18,01715,204
Prepaid expenses and other current assets1,5971,764
Total current assets88,808126,883
Property and equipment, net8,77510,268
Operating lease right-of-use assets6,4627,536
Other Assets  
Restricted cash462562
Other long-term assets8692
Total assets104,593145,341
Current liabilities  
Accounts payable6,5626,557
Accrued expenses9,0349,576
Operating lease liabilities1,9191,830
Total current liabilities17,51517,963
Long-term debt, less debt issuance costs20,48020,355
Operating lease liabilities5,4336,471
Total liabilities43,42844,789
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.00001 par value: Authorized: 5,000,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued and outstanding as of June 30, 2022 and December 31, 202100
Common stock, $0.00001 par value: Authorized: 300,000,000 shares authorized at June 30, 2022 and December 31, 2021; 185,332,724 and 186,042,390 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively22
Additional paid-in capital634,892632,513
Accumulated deficit(577,608)(530,851)
Accumulated other comprehensive income (loss)3,879(1,112)
Total stockholders’ equity61,165100,552
Total liabilities and stockholders’ equity$ 104,593$ 145,341